2013 Fiscal Year Final Research Report
Synoviolin inhibitors for treatment of fibrosis
| Project/Area Number |
23659502
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
膠原病・アレルギー・感染症内科学
|
|---|
| Research Institution | St. Marianna University School of Medicine |
|---|
Principal Investigator |
YAGISHITA Naoko 聖マリアンナ医科大学, 医学(系)研究科(研究院), 講師 (40367389)
|
|---|
| Project Period (FY) |
2011 – 2012
|
| Keywords | 関節リウマチ / 滑膜細菌 / シノビオリン / 小胞体関連分解 / 線維化 / 阻害剤 |
|---|
| Research Abstract |
Rheumatoid arthritis (RA) significantly affects quality of life. We recently cloned synoviolin, an E3 ubiquitin ligase implicated in the endoplasmic reticulum-associated degradation pathway. Synoviolin is highly expressed in rheumatoid synovial cells and is involved in the pathogenesis of RA. Inhibition of synoviolin activity is a potentially useful therapeutic approach for the treatment of RA. We recently identified two classes of small molecules, named LS-101 and LS-102, which inhibited synoviolin activity. LS-102 selectively inhibited synoviolin enzymatic activity, while LS-101 inhibited a broad array of RING-type E3 ligases. Moreover, these inhibitors suppressed the proliferation of rheumatoid synovial cells, and significantly reduced the severity of disease in a mouse model of RA and liver fibrosis. Our results suggest that inhibition of synoviolin is a potentially useful approach in the treatment of fibrosis.
|
Research Products
(12 results)
-
-
[Journal Article] The Japanese version of the 2010 American College of Rheumatology Preliminary Diagnostic Criteria for Fibromyalgia and the Fibromyalgia Symptom Scale : reliability and validity2012
Author(s)
Usui C, Hatta K, Aratani S, Yagishita N, Nishioka K, Kanazawa T, Ito K, Yamano Y, Nakamura H, Nakajima T, Nishioka K
-
Journal Title
Mod Rheumatol
Volume: 22(1)
Pages: 40-44
DOI
Peer Reviewed
-
-
-
-
-
-
-
-
-
-
